
## Ana C Puhl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3092868/publications.pdf Version: 2024-02-01



ΔΝΛ C ΡΠΗΙ

#	Article	IF	CITATIONS
1	Pyronaridine Protects against SARS-CoV-2 Infection in Mouse. ACS Infectious Diseases, 2022, 8, 1147-1160.	3.8	14
2	Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1. ACS Omega, 2021, 6, 3186-3193.	3.5	11
3	The Antiviral Drug Tilorone Is a Potent and Selective Inhibitor of Acetylcholinesterase. Chemical Research in Toxicology, 2021, 34, 1296-1307.	3.3	15
4	Devising effective enzyme replacement therapy for infantile onset neuronal ceroid lipofuscinosis (CLN1 disease). Molecular Genetics and Metabolism, 2021, 132, S28.	1.1	2
5	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential Mechanisms. ACS Omega, 2021, 6, 7454-7468.	3.5	56
6	Development of Machine Learning Models and the Discovery of a New Antiviral Compound against Yellow Fever Virus. Journal of Chemical Information and Modeling, 2021, 61, 3804-3813.	5.4	16
7	Machine Learning Models Identify Inhibitors of SARS-CoV-2. Journal of Chemical Information and Modeling, 2021, 61, 4224-4235.	5.4	31
8	Recent advances in drug repurposing using machine learning. Current Opinion in Chemical Biology, 2021, 65, 74-84.	6.1	28
9	Discovery and Development of Cyclic Peptide Inhibitors of CIB1. ACS Medicinal Chemistry Letters, 2021, 12, 1832-1839.	2.8	14
10	Machine Learning for Discovery of GSK3Î <sup>2</sup> Inhibitors. ACS Omega, 2020, 5, 26551-26561.	3.5	22
11	Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. ACS Omega, 2020, 5, 29935-29942.	3.5	8
12	Discovery and Characterization of Peptide Inhibitors for Calcium and Integrin Binding Protein 1. ACS Chemical Biology, 2020, 15, 1505-1516.	3.4	11
13	Repurposing the Dihydropyridine Calcium Channel Inhibitor Nicardipine as a Nav1.8 Inhibitor In Vivo for Pitt Hopkins Syndrome. Pharmaceutical Research, 2020, 37, 127.	3.5	7
14	Déjà vu: Stimulating open drug discovery for SARS-CoV-2. Drug Discovery Today, 2020, 25, 928-941.	6.4	81
15	Crystallographic structure and molecular dynamics simulations of the major endoglucanase from Xanthomonas campestris pv. campestris shed light on its oligosaccharide products release pattern. International Journal of Biological Macromolecules, 2019, 136, 493-502.	7.5	5
16	Exploiting machine learning for end-to-end drug discovery and development. Nature Materials, 2019, 18, 435-441.	27.5	334
17	New targets for HIV drug discovery. Drug Discovery Today, 2019, 24, 1139-1147.	6.4	18
18	Industrializing enzyme replacement therapy development. Molecular Genetics and Metabolism, 2019, 126, S120.	1.1	0

ANA C PUHL

#	Article	IF	CITATIONS
19	Developing an enzyme replacement therapy and small molecule chaperone combination as a potential treatment for multiple sulfatase deficiency. Molecular Genetics and Metabolism, 2019, 126, S120-S121.	1.1	Ο
20	Structural dataset for the PPARÎ <sup>3</sup> V290M mutant. Data in Brief, 2016, 7, 1430-1437.	1.0	1
21	Mechanisms of Peroxisome Proliferator Activated Receptor Î <sup>3</sup> Regulation by Non-steroidal Anti-inflammatory Drugs. Nuclear Receptor Signaling, 2015, 13, nrs.13004.	1.0	63
22	Crystallization and preliminary diffraction analysis of the catalytic domain of major extracellular endoglucanase fromXanthomonas campestrispv.campestris. Acta Crystallographica Section F: Structural Biology Communications, 2013, 69, 137-140.	0.7	2
23	Mode of Peroxisome Proliferator-Activated Receptor Î <sup>3</sup> Activation by Luteolin. Molecular Pharmacology, 2012, 81, 788-799.	2.3	84